Your browser doesn't support javascript.
loading
Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases.
Pejovic, Tanja; Abate, Pierre-Valérien; Ma, Hongli; Thiessen, Jaclyn; Corless, Christopher L; Peterson, Abigail; Allard-Chamard, Hugues; Labrie, Marilyne.
Afiliação
  • Pejovic T; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
  • Abate PV; Department of Immunology and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Ma H; Department of Obstetrics and Gynecology, Université de Sherbrooke, Sherbrooke, QC, Canada.
  • Thiessen J; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
  • Corless CL; Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR, United States.
  • Peterson A; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
  • Allard-Chamard H; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States.
  • Labrie M; Service of Rheumatology, Department of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada.
Front Oncol ; 12: 903806, 2022.
Article em En | MEDLINE | ID: mdl-35692807
Between 2% and 6% of epithelial ovarian cancer (EOC) patients develop brain metastases (brain mets), which are incurable and invariably result in death. This poor outcome is associated with a lack of established guidelines for the detection and treatment of brain mets in EOC patients. In this study, we characterize an unusual case of low-grade serous ovarian carcinoma (LGSOC) that metastasized to the brain. Using a spatially oriented single-cell proteomics platform, we compared sequential biopsies of a primary tumor with a peritoneal recurrence and brain mets. We identified several targetable oncogenic pathways and immunosuppressive mechanisms that are amplified in the brain mets and could be involved in the progression of LGSOC to the brain. Furthermore, we were able to identify cell populations that are shared between the primary tumor and the brain mets, suggesting that cells that have a propensity for metastasis to the brain could be identified early during the course of disease. Taken together, our findings further a path for personalized therapeutic decisions in LGSOC.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos